Kristi Rosa

Associate Editorial Director, OncLive®
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource Contagion, strengthened the Rare Disease Report, of HCPLive, and now oversees OncLive and its flagship publication OncologyLive. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Articles

A Close Look at Clinical Trials in Oncology and Beyond: Recruitment and Inclusion

January 30th 2025

In this episode, experts highlight the increasing push to simplify cancer trial eligibility criteria and improve diversity in participant enrollment.

A Close Look at Clinical Trials in Oncology and Beyond: State of Affairs and Industry Progress

January 30th 2025

In this episode, experts discuss progress in cancer clinical trials and the challenges posed by the increasing complexity of therapies and protocols.

Dr Popat on the Efficacy and Safety Profiles of Zongertinib in HER2-Mutated NSCLC

January 30th 2025

Sanjay Popat, BSc, MBBS, FRCP, PhD, discusses data that have been reported with zongertinib in patients with HER2-mutated NSCLC.

A Close Look at Clinical Trials in Oncology and Beyond: Boosting Accessibility

January 30th 2025

In this episode, experts emphasize the importance of providing flexible clinical trial options, such as satellite sites and remote follow-ups.

A Close Look at Clinical Trials in Oncology and Beyond: Barriers to Participation

January 29th 2025

In this episode, experts discuss the challenges of increasing awareness and participation in clinical trials.

A Close Look at Clinical Trials in Oncology and Beyond: Incorporating Into Standard Care

January 28th 2025

In this episode, experts discuss the importance of integrating clinical trials as a standard of care, particularly in the realm of oncology.

Encorafenib/Cetuximab Plus Chemo Drives ORR Improvement in BRAF V600E+ mCRC

January 25th 2025

Encorafenib plus cetuximab and mFOLFOX6 improved responses in BRAF V600E–mutated metastatic colorectal cancer.

Botensilimab Plus Balstilimab Elicits Encouraging Responses in MSS mCRC Without Liver Mets

January 25th 2025

The contribution of balstilimab to botensilimab in patients with MSS mCRC without liver metastases has been confirmed in a phase 2 study.

Trifluridine/Tipiracil Demonstrates DFS Benefit Over Placebo in Resected Stage IV CRC

January 25th 2025

Trifluridine/tipiracil showed a numerical, but not significant, DFS improvement in all patients with residual disease after curative resection of CRC.

The OncFive: Top Oncology Articles for the Week of 1/19

January 25th 2025

Treosulfan wins FDA approval for allHCT conditioning in AML and MDS, RP1/nivolumab gets priority review in melanoma, and more this week from OncLive.

Dr Hinchcliff on the Evolving Role of PARP Inhibitors in Ovarian Cancer

January 25th 2025

Emily M. Hinchcliff, MD, MPH, discusses future research directions regarding the role of PARP inhibitors for the treatment of patients with ovarian cancer.

Certepetide Plus Gemcitabine and Nab-Paclitaxel Shows Preliminary Activity in Metastatic Pancreatic Cancer

January 25th 2025

Certepetide plus gemcitabine and nab-paclitaxel showed antitumor activity despite failing to improve PFS vs chemotherapy alone in untreated metastatic pancreatic cancer.

Pelareorep Plus mFOLFIRINOX ± Atezolizumab Shows Acceptable Safety in Metastatic PDAC

January 24th 2025

Pelareorep plus modified FOLFIRINOX with or without atezolizumab showed acceptable safety in newly diagnosed metastatic pancreatic ductal adenocarcinoma.

NIPS Boosts Overall Survival Over PS in Gastric Cancer With Peritoneal Metastasis

January 24th 2025

Intraperitoneal and intravenous paclitaxel plus S-1 improved OS over intravenous paclitaxel and S-1 alone in gastric cancer with peritoneal metastasis.

Tislelizumab Plus Chemotherapy Is Active, Tolerable in Advanced Gastric/GEJ Cancer

January 24th 2025

Tislelizumab plus irinotecan, paclitaxel, oxaliplatin, and 5-FU/leucovorin showcased encouraging efficacy and manageable safety in gastric/GEJ cancer.

Oncology Experts Preview Top Abstracts to be Shared at 2025 ASCO GI

January 22nd 2025

Tanios S. Bekaii-Saab, MD, and Yelena Y. Janjigian, MD, preview top presentations from this year’s Gastrointestinal Cancers Symposium.

The OncFive: Top Oncology Articles for the Week of 1/12

January 18th 2025

Sotorasib doublet gets approved for KRAS G12C–mutated CRC, acalabrutinib triplet is cleared for previously untreated MCL, and more from OncLive.

FDA Approves Sotorasib Plus Panitumumab for KRAS G12C–Mutated Colorectal Cancer

January 16th 2025

The FDA approved sotorasib plus panitumumab for adult select patients with KRAS G12C–mutated metastatic colorectal cancer.

FDA Approves Acalabrutinib Plus Bendamustine and Rituximab for Previously Untreated MCL

January 16th 2025

The FDA has approved acalabrutinib plus bendamustine and rituximab for adult patients with previously untreated MCL who are ineligible for autologous HSCT.

Tabelecleucel BLA Receives FDA CRL in Pretreated EBV+ Post-Transplant Lymphoproliferative Disease

January 16th 2025

The FDA issued a CRL to the BLA of tabelecleucel in EBV+ PTLD following at least 1 prior line of treatment.